We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
White initials JT on a dark background.

Jonathan Tobin, PhD, MBA profile page

Investor-in-Residence

 at Cancer Research Horizons

Jonathan is an investor-in-residence at Cancer Research Horizons and a partner at Brandon Capital.

Jonathan has a degree in biology from the University of Oxford, a PhD in molecular medicine from UCL focusing on rare genetic diseases, and an MBA with distinction from Imperial College London.


Education

University of Oxford  

University College London  

Imperial College London  


Areas of Expertise

Biotechnology
Investments
In vivo CAR T therapy

Got a Question for Jonathan Tobin, PhD, MBA?

Get in touch using the contact form linked here and we'll get back to you shortly.



Content Written By, Reviewed By, or Featuring Jonathan Tobin, PhD, MBA
Total: 1
A cancer cell with a target over it and immune cells surrounding, illustrating immunotherapy.
Article

Will In Vivo CAR T Therapy Transform Cancer Treatment?

In vivo CAR T therapy engineers immune cells directly in the body, offering a simpler, scalable alternative to ex vivo approaches. Early data show promise, but challenges in safety, targeting precision, and large-scale validation remain.
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter